Lyme Disease Vaccine Crosses European Review Threshold, but Statistical Questions Remain Behind 70% Protection
The EMA has accepted the marketing authorization application for Pfizer and Valneva’s hexavalent vaccine VLA15; the Phase 3 trial showed approximately 70% protection, but the primary analysis did not meet the prespecified statistical criterion, and acceptance does not mean approval.